Picture loading failed.

Anti-SEMA4D therapeutic antibody (Pre-made Pepinemab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Pepinemab is a humanised IgG4 monoclonal antibody against the semaphorin 4D (SEMA4D; CD100), being developed by Vaccinex for the treatment of multiple cancers, Alzheimer's disease and Huntington's disease.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-437-1mg 1mg 3090
GMP-Bios-ab-437-10mg 10mg 21890
GMP-Bios-ab-437-100mg 100mg 148000
GMP-Bios-ab-437-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-SEMA4D therapeutic antibody (Pre-made Pepinemab biosimilar,Whole mAb)
INN Name Pepinemab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesBristol-Myers Squibb;Children's Oncology Group;Emory University;Merck KGaA;National Cancer Institute (USA);Teva Pharmaceutical Industries;UCLAs Jonsson Comprehensive Cancer Center;Vaccinex
Conditions Approvedna
Conditions ActiveHuntington's disease;Non-small cell lung cancer;Osteosarcoma;Solid tumours;Colorectal cancer;Head and neck cancer;Malignant melanoma;Pancreatic cancer
Conditions DiscontinuedMultiple sclerosis
Development Techna